JNJ-78278343、進行性前立腺癌に対するヒト カリクレイン 2 (KLK2) を標的とする T 細胞リダイレクト剤の研究
JNJ-78278343、ヒト カリクレイン 2 (KLK2) を標的とする T 細胞リダイレクト剤の進行性前立腺癌に対する第 1 相試験
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10032
- Columbia University Medical Center Herbert Irving Pavilion
-
-
Washington
-
Seattle、Washington、アメリカ、98195-9472
- University of Washington
-
-
-
-
-
Amsterdam、オランダ、1066 CX
- Antoni van Leeuwenhoek
-
Rotterdam、オランダ、3015 GD
- Erasmus MC
-
-
-
-
-
Madrid、スペイン、28040
- Hosp Univ Fund Jimenez Diaz
-
Madrid、スペイン、28050
- Hosp Univ Hm Sanchinarro
-
Málaga、スペイン、29010
- Hosp Virgen de La Victoria
-
-
-
-
-
Lyon、フランス、69373
- Centre Leon Berard
-
Marseille、フランス、13005
- APHM Hopital Timone
-
Villejuif、フランス、94800
- Institut Gustave Roussy
-
-
-
-
-
Beijing、中国、100191
- Peking University Third Hospital
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Guangzhou、中国、510710
- Sun Yat Sen University Cancer Center
-
Wenzhou、中国、325399
- First Affiliated Hospital Of Wenzhou Medical College
-
-
-
-
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Yokohama、日本、232 0024
- Yokohama City University Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Confirmed adenocarcinoma of the prostate which has spread to other body parts
- Part 1: Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
- Measurable or evaluable disease
- Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog
Exclusion Criteria:
Disease conditions
- Active central nervous system (CNS) involvement
- Toxicity related to prior anticancer therapy has not adequately recovered
Prior/Concomitant Therapy
- Prior treatment with human kallikrein (KLK) 2-targeted therapy
- Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug
- Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug
Prior/Concurrent Medical Conditions
- Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug
- Solid organ or bone marrow transplantation
- Major clotting diseases within one month prior to the first dose of study drug
- Active autoimmune disease within 12 months prior to the first dose of study drug
- Active infection
- Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug
- Clinically significant lung diseases
- Active or chronic hepatitis B or hepatitis C infection
- Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)
- Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:JNJ-78278343
Participants will receive JNJ-78278343. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 at recommended phase 2 dose (RP2D) as determined in Part 1. Participants who are still on study treatment (i.e., who are in Treatment Phase) at the time of the long term extension (LTE) will continue to receive study treatment until they reach a reason for discontinuation of treatment or until further notification by the sponsor of a different means for continued supply of study treatment, whichever occurs first. |
JNJ-78278343 will be administered. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 and 2: Number of Participants With Adverse Events (AEs)
時間枠:Up to 1 year and 10 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year and 10 months
|
|
Part 1 and 2: Number of Participants With AEs by Severity
時間枠:Up to 1 year and 10 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. |
Up to 1 year and 10 months
|
|
Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
時間枠:Up to 1 year and 10 months
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 1 year and 10 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Serum Concentration of JNJ-78278343
時間枠:Up to 1 year and 10 months
|
Serum concentrations of JNJ-78278343 will be determined. |
Up to 1 year and 10 months
|
|
Systemic Cytokine Concentrations
時間枠:Up to 1 year and 10 months
|
Cytokine concentrations will be determined for biomarker assessment. |
Up to 1 year and 10 months
|
|
Serum Prostate Specific Antigen (PSA) Concentration
時間枠:Up to 1 year and 10 months
|
Serum PSA concentration will be measured. |
Up to 1 year and 10 months
|
|
Number of Participants With Anti-JNJ-78278343 Antibodies
時間枠:Up to 1 year and 10 months
|
Serum samples will be analyzed for the detection of anti-JNJ-78278343 antibodies using a validated assay method. |
Up to 1 year and 10 months
|
|
Objective Response Rate (ORR)
時間枠:Up to 1 year and 10 months
|
ORR is defined as the percentage of participants who have a partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version 1.1 response criteria without evidence of bone progression according to prostate cancer working group 3 (PCWG3). |
Up to 1 year and 10 months
|
|
Radiographic Progression-free Survival (rPFS)
時間枠:Up to 1 year and 10 months
|
rPFS is defined as time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first. |
Up to 1 year and 10 months
|
|
PSA Response Rate
時間枠:Up to 1 year and 10 months
|
PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline. The maximum reduction from baseline in PSA will also be calculated during the treatment. |
Up to 1 year and 10 months
|
|
Duration of Response (DOR)
時間枠:Up to 1 year and 10 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to 1 year and 10 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CR108958
- 2020-005970-83 (EudraCT番号)
- 78278343PCR1001 (その他の識別子:Janssen Research & Development, LLC)
- 2023-506585-31-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。